Skip to main content
SpringerLink
Log in

Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Association of p53 gene abnormalities with tumor progression and prognosis of many neoplasms has been demonstrated, but little is known about the clinical significance of p53 abnormalities in meningiomas. The significance of p53 protein expression in recurrent meningiomas and its relationships with MDM2 protein and proliferation activity were investigated by analyzing 39 meningiomas immunohistochemically. p53 protein was expressed in 11 (35%) of 31 non-recurrent and 7 (88%) of 8 recurrent meningiomas. A high frequency of p53 expression was observed in recurrent meningiomas, which tended to have a high p53 positive index (p53 PI), indicating that p53 immunoreactivity may be a marker for predicting tumor recurrence. Four recurrent meningiomas with high p53 PIs were analyzed by the polymerase chain reaction-single strand conformation polymorphism method to detect p53 gene mutations, but none were found in exons 4–8 of this gene. Fifteen (71%) of 21 MDM2-positive and 3 (17%) of 18 MDM2-negative tumors expressed p53 protein, showing that MDM2 expression was more common in meningiomas with p53 expression. p53 immunoreactivity in the absence of mutation may indicate stabilization of the wild type through interaction with the MDM2 protein. The Ki-67/MIB-1 proliferation index (MIB-1 PI) correlated well with recurrence. The p53-positive tumors had a significantly higher mean MIB-1 PI than p53-negative tumors, suggesting that wild-type p53 inactivation by the MDM2 protein may be involved in controlling the proliferative activity in meningiomas. In conclusion, immunohistochemical examination for p53 protein as well as proliferative activity may help predict the malignant potential of tumor recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49–53, 1991

    Google Scholar 

  2. Marx J: How p53 suppresses cell growth. Science 262: 1644–1645, 1993

    Google Scholar 

  3. Chang F, Syrjänen S, Tervahauta A, Syrjänen K: Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653–661, 1993

    Google Scholar 

  4. Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO: Expression of the p53 protein in a spectrum of astrocytic tumours. J Pathol 168: 383–386, 1992

    Google Scholar 

  5. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373–385, 1992

    Google Scholar 

  6. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD, Kleihues P: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8: 74–80, 1993

    Google Scholar 

  7. Oliner JD, Kinzler KW, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83, 1992

    Google Scholar 

  8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245, 1992

    Google Scholar 

  9. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860, 1993

    Google Scholar 

  10. Wu X, Bayle JH, Olson D, Levine AJ: The p53-MDM-2 autoregulatory feedback loop. Genes Dev 7: 1126–1132, 1993

    Google Scholar 

  11. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M: Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 12: 2799–2808, 1993

    Google Scholar 

  12. Leach FS, Tokino T, Maltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231–2234, 1993

    Google Scholar 

  13. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739, 1993

    Google Scholar 

  14. Goelz SE, Hamilton SR, Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130: 118–126, 1985

    Google Scholar 

  15. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J: Analysis of p53 gene mutations in low-and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225–232, 1994

    Google Scholar 

  16. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874–879, 1989

    Google Scholar 

  17. Christensen D, Laursen H, Klinken L: Prediction of recurrence in meningiomas after surgical treatment. A quantitative approach. Acta Neuropathol (Berl) 61: 130–134, 1983

    Google Scholar 

  18. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, Matsuura R, Utsunomiya H, Kirino T: Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91: 504–510, 1996

    Google Scholar 

  19. Adegbite AB, Khan MI, Paine KW, Tan LK: The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58: 51–56, 1983

    Google Scholar 

  20. Paulus W. Meixensbergers J, Hofmann E, Roggendorf W: Effect of embolisation of meningioma on Ki-67 proliferation index. J Clin Pathol 46: 867–877, 1993

    Google Scholar 

  21. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M: MIB-1staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer 74: 3176–3189, 1994

    Google Scholar 

  22. Lindblom A, Ruttledge M, Collins VP, Nordenskjöld M, Dumanski JP: Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56: 354–357, 1994

    Google Scholar 

  23. Karamitopoulou E, Perentes E, Diamantis I: p53 protein expression in central nervous system tumours: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 85: 611–616, 1993

    Google Scholar 

  24. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC: Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 21: 136–142, 1995

    Google Scholar 

  25. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, Nister M: Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffinembedded samples. Int J Cancer 64: 223–228, 1995

    Google Scholar 

  26. Albrecht S, Gooodman JC, Rajagopolan S, Levy M, Cech DA, Cooley LD: Malignant meningioma in Gorlin's syndrome: cytogenetic and p53 gene analysis. J Neurosurg 81: 466–471, 1994

    Google Scholar 

  27. Chozick BS, Benzil DL, Stopa EG, Pezzullo JC, Knuckey NW, Epstein MH, Finkelstein SD, Finch PW: Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neurooncol 27: 117–126, 1996

    Google Scholar 

  28. Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J Pathol 172: 1–4, 1994

    Google Scholar 

  29. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523–526, 1992

    Google Scholar 

  30. Girod SC, Cesarz D, Fischer U, Krueger GR: Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res 15: 1453–1458, 1995

    Google Scholar 

  31. Martinez JC, Mateo M, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Garcia P, Lopez C, Martinez P, Piris MA: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 177: 27–34, 1995

    Google Scholar 

  32. Barak Y, Juven T, Haffner R, Oren M: MDM-2 expression is induced by wild type p53 activity. EMBO J 2: 461–468, 1993

    Google Scholar 

  33. Chen J, Marechal V, Levine A Jr: Mapping of the p53 and MDM2 interaction domains. Mol Cell Biol 13: 4107–4114, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Kyorin University School of Health Sciences, Tokyo, Japan

    Mitsuaki Ohkoudo, Hiroshi Yamamoto & Masahiko Fujii

  2. Department of Molecular Biology, Kyorin University School of Health Sciences, Tokyo, Japan

    Toshiko Aiso & Reiko Ohki

  3. Department of Neurosurgery, Kyorin University School of Medicine, Tokyo, Japan

    Hiroki Sawa, Mitsuhiro Hara, Kazuhiko Saruta & Isamu Saito

  4. Department of Neurosurgery, Akiru Municipal General Hospital, Tokyo, Japan

    Eiji Maemura

Authors
  1. Mitsuaki Ohkoudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroki Sawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuhiro Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhiko Saruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiko Aiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reiko Ohki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eiji Maemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshio Shiina
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiko Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Isamu Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohkoudo, M., Sawa, H., Hara, M. et al. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. J Neurooncol 38, 41–49 (1998). https://doi.org/10.1023/A:1005946001915

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005946001915

Search

Navigation